ECElisa Cannizzo

Elisa Cannizzo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elisa Cannizzo has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Giovanni Carulli

    Division of Hematology, Department of Oncology, Transplants and Advances in Medicine, University of Pisa, 56126 Pisa, Italy

    3 shared publications
  • Aliyah R. Sohani

    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston

    2 shared publications
  • Craig Sadowski

    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston

    2 shared publications
  • Frederic Preffer

    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

    2 shared publications
  • Janessa J. Bucci

    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston

    2 shared publications
  • Judith A. Ferry

    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston

    2 shared publications

Latest Publications

  • Open Access

    Discordant lymphoma consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood: a case report

    by Giovanni Carulli, Alessandra Marini, Eugenio M. Ciancia, Joseph Bruno, Silvana Vignati, Paola Lambelet, Elisa Cannizzo, Virginia Ottaviano, Sara Galimberti, Francesco Caracciolo, et al.

    Discordant lymphomas are rare entities characterized by the simultaneous presence of two distinct types of lymphomas in different anatomic sites. We describe a very rare case of simultaneous occurrence of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood.


  • Open Access

    Prethymic Cytoplasmic CD3 Negative Acute Lymphoblastic Leukemia or Acute Undifferentiated Leukemia: A Case Report

    by Elisa Cannizzo, Giovanni Carulli, Luigi Del Vecchio, Antonio Azzarà, Sara Galimberti, Virginia Ottaviano, Frederic Preffer, Mario Petrini

    Acute undiffentiated leukemia (AUL) is an acute leukemia with no more than one membrane marker of any given lineage. Blasts often express HLA-DR, CD34, and/or CD38 and may be positive for terminal deoxynucleotidyl transferase (TdT). The expression of CD34, HLA-DR, and CD38 has been shown in pro-T-ALL, although in this case, blasts should also express CD7 and cyCD3. However, some cases of T-ALL without CD3 in the cytoplasm and all TCR chain genes in germ line configuration are reported, features that fit well with a very early hematopoietic cell. We report a case of acute leukemia CD34+/−HLADR+CD7+CD38+cyCD3− in which a diagnosis of AUL was considered. However the blasts were also positive for CD99 and TCR delta gene rearrangement which was found on molecular studies. Therefore a differential diagnosis between AUL and an early cyCD3 negative T-ALL was debated.


  • Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology

    by Elisa Cannizzo, Emanuele Bellio, Aliyah R. Sohani, Robert P. Hasserjian, Judith A. Ferry, Michelle E. Dorn, Craig Sadowski, Janessa J. Bucci, Giovanni Carulli, Frederic Preffer

    Background: Numerous studies have reported on the immunophenotype of plasma cells (PCs) in monoclonal gammopathy of undetermined significance (MGUS) and in plasma cell myeloma (PCM), but very few have examined the immunophenotype of normal PCs. In this study, an objective definition of normal range of expression for each antigen was found on normal control PCs. Using these new ranges of normal expression (new method) is different from using a static 20% of PCs cut‐off for all antigens as described in the literature (traditional method). These newly calculated normal ranges for each antigen were applied to our data, and compared to histologic and immunohistochemical findings.Methods: Bone marrow samples from 46 patients with PC neoplasms and 15 normal controls were studied. A minimum of 100 PC were analyzed for each patient and control sample. An 8‐color staining method was applied to study the immunophenotype of PCs, using a BD FACSCanto II.Results: By the new ranges of normality calculated in this study it was determined that different antigens have different level of expression on polyclonal PCs. CD19 correlated with histology by both the traditional and new methods, but had superior correlation by the new method.Conclusions: This report is the first 8‐color immunophenotypic study of PCM in which a “range of normal expression” for each antigen is defined. This is a critical step to help distinguish between a normal and neoplastic PC immunophenotype and discern which antigens are of diagnostic importance. © 2010 Clinical Cytometry Society


  • Open Access

    Carcinoma and multiple lymphomas in one patient: establishing the diagnoses and analyzing risk factors

    by Elisa Cannizzo, Aliyah R. Sohani, Judith A. Ferry, Ephraim P. Hochberg, Michael J. Kluk, Michelle E. Dorn, Craig Sadowski, Janessa J. Bucci, Adam M. Ackerman, Janina A. Longtine, et al.

    Multiple malignancies may occur in the same patient, and a few reports describe cases with multiple hematologic and non-hematologic neoplasms. We report the case of a patient who showed the sequential occurrence of four different lymphoid neoplasms together with a squamous cell carcinoma of the lung. A 62-year-old man with adenopathy was admitted to the hospital, and lymph node biopsy was positive for low-grade follicular lymphoma. He achieved a partial remission with chemotherapy. Two years later, a PET-CT scan showed a left hilar mass in the lung; biopsy showed a squamous cell carcinoma. Simultaneously, he was diagnosed with diffuse large B cell lymphoma in a neck lymph node; after chemo- and radiotherapy, he achieved a complete response. A restaging PET-CT scan 2 years later revealed a retroperitoneal nodule, and biopsy again showed a low-grade follicular lymphoma, while a biopsy of a cutaneous scalp lesion showed a CD30-positive peripheral T cell lymphoma. After some months, a liver biopsy and a right cervical lymph node biopsy showed a CD30-positive peripheral T cell lymphoma consistent with anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. Flow cytometry and cytogenetic and molecular genetic analysis performed at diagnosis and during the patient’s follow-up confirmed the presence of two clonally distinct B cell lymphomas, while the two T cell neoplasms were confirmed to be clonally related. We discuss the relationship between multiple neoplasms occurring in the same patient and the various possible risk factors involved in their development.


    • 1 February 2009
      • Vol. 15  (2) , CS27-29

    Meningeal relapse in a case of B acute lymphoblastic leukemia: the role of CD56 expression.

    by Elisa Cannizzo, Giovanni Carulli, Gabriele Buda, Alessandra Zucca, Antonio Azzarà, Enrico Orciuolo, Mario Petrini

    Blasts from B acute lymphoblastic leukemia (B-ALL) may express CD56 in about 10% of cases. The presence of this marker at diagnosis is associated with an increased risk of meningeal relapse. A case is described of B-ALL which was CD56 negative at diagnosis, and expressed this marker when isolated meningeal relapse was diagnosed. A 53-year-old female patient presented with neurological symptoms during maintenance therapy for B-ALL. Peripheral blood, bone marrow, and cerebrospinal fluid (CSF) were subjected to both morphological and flow cytometric analyses. The latter was carried out by a wide routine panel of MoAbs which was the same as the one at diagnosis and included CD56. Isolated meningeal relapse was diagnosed since blast cell infiltration was detected in the CSF, but not in the peripheral blood and bone marrow samples. Blast cells showed an immunological phenotype similar to that at diagnosis (cyCD79a+, CD79b+, CD19+, CD22+, CD34+, CD10+, CD20+), but characterized by the acquisition of CD56 on the surfaces of more than 90% of cells. This case shows that CD56 can be expressed at relapse of B-ALL and that its presence likely enables leukemic cell binding to the central nervous system (CNS). This phenomenon may be responsible for the isolated CNS relapse diagnosed in this patient.